PSMA PET分期对新诊断前列腺癌初始治疗的影响
共纳入9,049例新诊断的不利中危、高危和极高危前列腺癌患者,结果显示PSMA PET分期与更高的ADT和ARPI使用率、更低的前列腺切除率相关,且PSMA分期N1M0和M1患者ARPI使用率显著高于N0M0。
要点
- PSMA PET分期与初始ADT使用率升高相关(aHR 1.26;95% CI 1.19-1.44)。
- PSMA PET分期与ARPI使用率升高相关(aHR 1.52;95% CI 1.33-1.78)。
- PSMA PET分期与前列腺切除率降低相关(aHR 0.69;95% CI 0.56-0.83)。
核心结论
- 在新诊断不利中危、高危和极高危前列腺癌患者中,PSMA PET分期可能与更少的前列腺切除术以及更高的ADT和ARPI使用率相关。
主要发现
- 共9,049例患者符合纳入标准。
- 与常规分期相比,PSMA PET分期与更高的任何ADT使用率相关(aHR 1.26;95% CI 1.19-1.44)。
- PSMA PET分期与更高的ARPI使用率相关(aHR 1.52;95% CI 1.33-1.78)。
- PSMA PET分期与更低的前列腺切除率相关(aHR 0.69;95% CI 0.56-0.83)。
- PSMA PET分期对放疗使用无显著影响(aHR 1.10;95% CI 0.99-1.25)。
关键数值与推荐
- 与PSMA分期N0M0患者相比,PSMA分期N1M0患者ARPI使用更常见(aHR 6.87;95% CI 5.41-8.73)。
- 与PSMA分期N0M0患者相比,PSMA分期M1患者ARPI使用更常见(aHR 10.13;95% CI 8.16-1.2.58)。
- PSMA分期N1M0患者接受前列腺切除术的可能性远低于PSMA分期N0M0患者。
临床怎么用
- 对于新诊断的不利中危、高危和极高危前列腺癌患者,PSMA PET分期可能影响初始治疗决策,倾向于减少前列腺切除术并增加ADT和ARPI的使用。
- 临床医生应意识到PSMA PET分期结果可能引导治疗向系统治疗倾斜,需结合患者具体情况综合判断。
局限性
- 本研究为观察性数据模拟随机对照试验,可能存在未测量的混杂因素。
- 研究人群为美国退伍军人健康管理局患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) PET/CT has become a common staging modality for newly diagnosed high-risk and unfavorable intermediate-risk prostate cancer after showing improved sensitivity and specificity compared with conventional imaging in clinical trials. We aimed to assess the causal impact of PSMA PET staging on initial treatment selection in real-world practice. Methods: We used observational data from the U.S. Veterans Health Administration to emulate a randomized controlled trial in which patients with newly diagnosed, unfavorable intermediate-, high-, and very-high-risk prostate cancer from January 2022 to December 2023 would have been randomized to undergo either upfront 18F- or 68Ga-PSMA PET staging or conventional imaging (99mTc bone scan and pelvic CT or MRI). Outcomes of interest included use of frontline androgen deprivation therapy (ADT), second-generation androgen receptor pathway inhibitors (ARPIs), radiotherapy, and radical prostatectomy. Weighted univariable Cox regression was performed to assess the effect of treatment group on each outcome, and 95% CIs were generated from 1,000 bootstrap replicates. Results: In total, 9,049 patients met the criteria for inclusion. PSMA PET staging was associated with higher rates of any ADT use relative to conventional staging (adjusted hazard ratio [aHR], 1.26; 95% CI, 1.19-1.44), higher rates of ARPI use (aHR, 1.52; 95% CI, 1.33-1.78), lower rates of prostatectomy (aHR, 0.69; 95% CI, 0.56-0.83), and no significant effect on the use of radiotherapy (aHR, 1.10; 95% CI, 0.99-1.25). Compared with patients with PSMA stage N0M0, ARPI use was more common in patients with PSMA stage N1M0 (aHR, 6.87; 95% CI, 5.41-8.73) and PSMA stage M1 (aHR, 10.13; 95% CI, 8.16-1.2.58). Patients with PSMA N1M0 disease were much less likely to undergo prostatectomy compared with PSMA N0M0. Conclusion: PSMA PET staging may be leading to fewer prostatectomies and higher use rates of ADT and ARPIs in the Veterans Health Administration.
引用
- Miller SR, Chung DH, Gonzalez RT, et al. Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer. J Nucl Med. 2025. PMID: 41101975. doi:10.2967/jnumed.125.270825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。